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Multiple sclerosis (MS) shows distinct clinical courses. Experimental autoimmune encephalomyelitis
(EAE), a model to study multiple sclerosis, can be induced by different protocols, which show distinct
cytokine and antibody production. The factors involved in this heterogeneity remain unclear. The rele-
vance of MOG concentration in triggering a regulatory response in the chronic model of EAE is imprecise.
The aim of this study was investigate if 100 or 300 lg of MOG35–55 could induce different EAE proﬁles.
Modiﬁcations in the concentration of MOG were able to change the patterns of chemokines, cytokines,
percentage of cells, inﬂammatory inﬁltrate and the development of a regulatory response. However,
these changes were unable to modify the intensity of response, which explains the chronic progression
of the disease in both concentrations. The results presented in this study contribute to understanding
the intricate mechanisms that trigger EAE and provide insights into the pathogenesis of various forms
of MS.
 2015 Elsevier Inc. All rights reserved.1. Introduction secondary-progressive course is characterized by the RR in the ini-Multiple sclerosis (MS) is an autoimmune inﬂammatory demy-
elinating disease of the central nervous system (CNS) [1,2]. MS is
characterized by heterogeneous clinical, pathological and immu-
nological phenotypes that might better be described as a syndrome
rather than a single disease entity, a concept that has important
implications with respect to the development of effective thera-
peutic strategies [1–3].
There are four distinct clinical courses observed in patients with
multiple sclerosis: the relapsing–remitting, the most frequent
form; the secondary-progressive; the primary-progressive and
the progressive-relapsing courses. The relapsing–remitting (RR)
course is characterized by relapses followed by complete recovery
or with sequelae and residual deﬁcit upon recovery [2,4,5]. Thetial phase, with consequent progression of the disease and
relapses. The primary-progressive course is characterized by pro-
gression from onset with temporary amelioration. In the progres-
sive-relapsing course, there is a constant progression of the
disease, with clear acute relapses [4,5]. However, the factors
involved in this heterogeneity of MS are not completely under-
stood, highlighting the importance of the use of experimental mod-
els in the effort to elucidate the MS clinical courses [5].
Experimental autoimmune encephalomyelitis (EAE), a model to
study MS, is characterized by inﬁltration of T-helper (Th) 1 and
Th17 and cytokines relating to these cells, such as IFN-c and IL-
17 [6]. EAE can follow different disease courses, with diverse
inﬂammatory process, which could mimic the forms of MS, but
the mechanisms of these alterations are still unclear. Several
research groups have tested different EAE induction protocols to
determine the role of antigens and adjuvants in the progression
of MS [5,7–9]. A previous study induced EAE, with different con-
centrations of myelin oligodendrocyte glycoprotein (MOG) and
adjuvants, which modiﬁed the clinical course of the disease, with
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mice is determined by both genetic factors and the immunogenic/
adjuvant used to induce disease.
In the EAE models, progression and remitting are controlled by
the regulatory response [10]. The progression followed by com-
plete remitting results from an established regulatory response
able to promote recovery and stop relapsing. On the other hand,
chronic and RR forms have inefﬁcient regulatory response, which
prevents the complete remitting of the disease [10].
MOG is a smaller constituent of the myelin, and is a well-char-
acterized target antigen to study autoimmune responses in the
CNS [11–14]. MOG-deﬁcient mice have mild EAE, compared to
the wild type mice, which shows the importance of this peptide
in the generation of encephalomyelitis [14]. However, the rele-
vance of MOG concentration in triggering a regulatory response
in the chronic model of EAE remains unclear. The study of these
gaps could favor the understanding of the EAE model.
With the aim to shed new light on these issues, the kinetics of
regulatory and inﬂammatory mediators in the development of
EAE with different MOG concentrations was evaluated. The results
of this study show that different MOG35–55 concentrations were
unable to modify the clinical course of EAE, even though the lowest
concentration induced a regulatory response in the CNS.
2. Materials and methods
2.1. Animals
Female C57BL/6 mice, 4–6 weeks old, were obtained from the
animal care facilities of the Federal University of Juiz de Fora (UFJF)
and maintained in micro isolator cages. All procedures were in
accordance with the principles of the Brazilian Code for the Use
of Laboratory Animals. All protocols involving mice handling were
approved by the Committee on the use of laboratory animals from
UFJF (Protocol 07/2011).
2.2. EAE induction
The mice were divided in three experimental groups: non
immunized group, immunized group with 100 lg of MOG35–55
and immunized group with 300 lg of MOG35–55. The groups were
evaluated at days 7, 10, 14, 21 and 58 postimmunization. The mice
of the immunized groups were sub-cutaneous injected at the tail
base with 100 or 300 lg of myelin oligodendrocyte glycoprotein
peptide MOG35–55 emulsiﬁed v/v in complete Freund’s adjuvant
(Sigma Chemical Co., Saint Louis, USA) supplemented with
400 lg of attenuated Mycobacterium tuberculosis H37RA (Difco,
Detroit, USA), the MOG35–55 was synthesized in the laboratory of
Biophysics of the Federal University of São Paulo. Pertussis toxin
300 ng/animal (Sigma Chemical Co., Saint Louis, USA) was injected
intraperitoneally (i.p.) on the day and after 2 days of immuniza-
tion. Animals were monitored daily and neurological impairment
was quantiﬁed.
2.3. Clinical assessment
Mice were weighed and the clinical signs of EAE observed daily
for up to 58 days. The clinical status was assessed individually
according to previous study [15,16]. The ﬁnal clinical score was
obtained adding all individual scores assessed.
2.4. Histological staining
To evaluate brain and spinal cord tissue histology, groups of
mice (n = 6) were euthanized under anesthesia, perfused by intra-
cardiac puncture with 5 ml of 4% buffered formalin at days 7, 10,14, 21 and 58 postimmunization. The brains or spinal cords were
ﬁxed in 4% buffered formalin and embedded in parafﬁn. 5-lm-
thick sections were stained with hematoxylin and eosin (H&E) to
assess tissue damage and inﬂammation. The mean score of inﬂam-
mation (MSI) in the brain and spinal cord of each animal were eval-
uated blindly, in each slide, using a semi quantitative system as
previously described [17]. 10-lm-thick sections of spinal cord of
58 day postimmunization were stained with Luxol fast blue (LFB)
– cresyl violet, to access the demyelination.
2.5. Cytokines and chemokines production
At days 7, 10, 14, 21 and 58 postimmunization mice were
euthanized under anesthesia (i.p.) and perfused through the left
ventricle with phosphate buffered saline (PBS). Brains, spinal cords
and lymph nodes of 6 mice per group were removed and homoge-
nized (100 mg/ml) in the extraction solution containing 0.4 M
NaCl, 0.05% tween 20 (Merck & Co., Inc., Whitehouse Station,
USA), 0.5% bovine serum albumin (BSA), 0.1 M phenylmethylsul-
fonyl ﬂuoride (PMSF), 0.1 M benzethonium chloride, 10 mM ethyl-
enediaminetetraacetic acid (EDTA) and 20 kIU/ml aprotinin (Sigma
Chemical Co., Saint Louis, USA). The homogenate was centrifuged
at 2000g for 15 min at 4 C and supernatants were collected to
determine the concentration of IFN-c, IL-17A, IL-6, TGF-b and
IL-10. CCL5 and CCL20 were determined only in the brain.
Cytokines and chemokines production were assayed by ELISA
using commercially available antibodies according to the manufac-
turer’s instructions (BD Biosciences Pharmingen, San Diego, USA).
2.6. Isolation of brain mononuclear cells
At days 7 and 10 after induction, eight mice of each group were
euthanized under anesthesia (i.p.) and perfused through the left
ventricle with PBS. Brains were removed, macerated and ﬁltered
using 70 lm cell strainer (BD Biosciences, Bedford, USA) in RPMI
1640 medium (Gibco, Grand Island, USA) with 10% fetal bovine
serum (FBS) (Gibco, Grand Island, USA). Dispersed brain cells were
incubated in RPMI containing 2 mg of collagenase D (Roche, Mann-
heim, Germany) at 37 C for 45 min. Brain mononuclear cells were
collected after Percoll density gradient centrifugation and washed
with staining buffer (PBS, 1% FBS, 0.09% sodium azide) [18]. The
cell pellet was suspended in ACK solution, centrifuged at 350g
for 5 min, and suspended in staining buffer for ﬂow cytometry
analysis.
2.7. Flow cytometry analysis
Isolated mononuclear brain cells were incubated with anti-
mouse CD3-APC and anti-mouse CD4-PerCP (BD Biosciences
PharMingen, San Diego, USA). After 30 min at 4 C, cells were
washed in staining buffer and permeabilized with BDPharmingen
Fix/Perm solution, washed in BD Pharmingen Perm/Wash Buffer,
and then stained with anti-mouse IL-17-Alexa Fluor 488 and
anti-mouse IFN-c- PE (BD Biosciences PharMingen, San Diego,
USA). After 30 min at 4 C, cells were acquired and analyzed using
a FACScalibur ﬂow cytometer and CellQuest software (Becton Dick-
inson, San Diego, USA).
2.8. Statistics
The present results are representative of three independent
experiments, shown as the mean ± SEM. The signiﬁcance of differ-
ences between groups was analyzed using a Student’s t-test,
Mann–Whitney test, or two-way ANOVA (GraphPad Prism 5.00)
when appropriate. The differences were considered signiﬁcant
when p < 0.05.
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3.1. EAE induced with 100 or 300 lg of MOG35–55 showed the same
clinical course
All immunized animals developed clinical signs with no
difference between groups in the peak of clinical score (4.8 ± 0.3
versus 4.7 ± 0.2) and the end-stage mean score (day 58; 3.8 ± 0.4
versus 4.1 ± 0.5) (Fig. 1A). Tail paralysis and hind limb
weakness were the major clinical features observed. Concomi-
tantly with the clinical symptoms above, there was signiﬁcant
weight loss between days 11 and 21 after immunization in both
immunized groups, when compared to the non-immunized group
(Supplementary 1).3.2. The 100 lg MOG35–55 group had earlier inﬂammatory inﬁltrate in
the CNS
The presence of inﬂammatory inﬁltrate in the brain and spinal
cord of EAE-inducedmice on days 7, 10, 14, 21 and 58 after immuni-
zation was assessed through histological analysis. The non-immu-
nized group showed standard CNS histology (Supplementary 2).Fig. 1. C57BL/6 immunized with 100 or 300 lg of MOG35–55 showed the same clin
inﬂammation in the brain (B) and spinal cord (C) of C57BL/6 non immunized and immuni
(n = 14 per group) were registered from day 0 to day 58 postimmunization. Each point rep
10, 14, 21 and 58 days postimmunization. Each bar represents the arithmetic mean ± S
different experiments.In the brain, only the group immunized with 100 lg MOG35–55
showed cellular inﬁltration on day 7. Both immunized groups
showed the presence of inﬂammatory inﬁltrate on day 10. On days
14 and 21 after immunization, inﬁltrate levels were higher in the
100 lg MOG35–55 group, compared to the 300 lg MOG35–55 group.
On the 58th day after immunization, a reduction in inﬂammatory
inﬁltrate levels was observed in the brain (Supplementary 2). Only
the 100 lg MOG35–55 group presented MSI (MSI = 2.0 ± 0.2) on day
7. The peak of MSI for immunized groups was observed on day 14.
Fifty-eight days after immunization, MSI was reduced, and no sig-
niﬁcant differences were observed between the immunized groups
(Fig. 1B).
For the spinal cord, the cellular inﬁltrate was observed only in
the 100 lg MOG35–55 group on days 7 and 10 after immunization.
On days 14 and 21 after immunization, the inﬁltrate level was
higher in the 300 lg MOG35–55 group (Supplementary 3). As in
the histology analysis, only the 100 lg MOG35–55 group presented
MSI on days 7 and 10, while on days 14 and 21, MSI was higher for
the 300 lg MOG35–55 group (Fig. 1C). On day 58 after immuniza-
tion, the degree of cellular inﬁltrate and MSI were reduced, though
signiﬁcant differences were not observed between the immunized
groups (Fig. 1C and Supplementary 3); however, demyelination
was present (Fig. 2). Demyelination was observed on day 58 afterical course and different inﬂammatory progress. Clinical score (A) and score of
zed with 100 or 300 lg of myelin oligodendrocyte (MOG35–55) peptide. Clinical score
resents mean ± SEM. The score of inﬂammation (n = 6 per group) was evaluated at 7,
EM. ⁄p < 0.05 versus 300 lg of MOG35–55 group. Results are representative of three
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in the group immunized with 100 lg MOG35–55 than in the 300 lg
MOG35–55 group (Fig. 2).
3.3. Cytokines production
The levels of IFN-c, IL-17A, IL-6, TGF-b and IL-10 were analyzed
in supernatants of macerated brains, spinal cords and lymph nodes
on days 7, 10, 14, 21 and 58. The concentrations of cytokines in the
brain were detected earlier, with production peaks on day 7, in the
100 lg MOG35–55 group. In the 300 lg MOG35–55 group, cytokines
were detected from day 10 on, with production peaks on day 10
(Supplementary 4). In the spinal cord, only IFN-c of the 300 lg
MOG35–55 group was not detected on day 7 (Supplementary 5).
The production peak followed a similar pattern in the brain and
in the spinal cord for the 100 lg MOG35–55 group; however, in
the 300 lg MOG35–55 group, cytokines had a production peak in
the spinal cord after the onset of the disease. On the other hand,
oppositely to what was observed in the CNS, in lymph nodes all
cytokines were detected from day 7 on in the 300 lg MOG35–55
group, while in the 100 lg MOG35–55 group, cytokines were
detected from day 10 on, with production peak on day 21 (Supple-
mentary 6). In relation to IL-10 and TGF-b, the 100 lg MOG35–55
group showed a high production of these cytokines in the CNS on
day 7. The same ﬁnding was observed for the 300 lg MOG35–55
group on day 10, but the opposite was observed in lymph nodes
(Fig. 3).
3.4. CCL5 and CCL20 were ﬁrst produced in the brains of the 100 lg
MOG35–55 group
In addition to the evaluation of inﬂammatory cell inﬁltrate, the
levels of CCL5 and CCL20 were analyzed in supernatants of macer-Fig. 2. Demyelination was evaluated in the spinal cords. Demyelination was
evaluated in the spinal cords of C57BL/6 mice non immunized and immunized with
100 or 300 lg of myelin oligodendrocyte (MOG35–55) peptide (n = 6 per group) at
58th day postimmunization (d.p.i.). The ﬁgures are representative of the histolog-
ical analysis of experimental group stained with Luxol fast blue and captured at a
magniﬁcation of 40, bar scale = 20 lm. Results are representative of three
different experiments.ated brains on days 7, 10, 14, 21 and 58. High levels of both chemo-
kines were detected on day 7 only in the 100 lg MOG35–55 group,
and remained so until day 21. In the 300 lg MOG35–55 group, che-
mokines were detected only on day 10 and 14, and returned to
control levels from day 21 on (Fig. 4).3.5. The frequency of CD4+IL-17+ T cells and CD4+IFN-c+ T cells was
elevated in the brains of immunized groups
The percentage of CD4+IL-17+ cells was higher in the group
immunized with 100 lg MOG35–55 on day 7 after immunization
(Fig. 5). The frequency of cells expressing CD4+IFN-c+ was higher
on day 10 after immunization, for both immunized groups (Fig. 5).4. Discussion
The EAE model has been studied for decades as an animal model
to understand the pathogenesis and progression of MS [19,20]. In
this context, different EAE models can be developed with diverse
clinical progression courses, such as complete remitting, relaps-
ing–remitting or chronic progression. The incomplete remitting
course in chronic and RR models could be explained in part by
the absence of a regulatory response. The regulatory response in
this model is well studied, and has been linked to the establish-
ment of a tolerance to self-antigens; moreover, treatments that
induce a regulatory response are related to the improvement of
clinical signs [21–23].
In the present study, the different concentrations of MOG were
able to trigger differentiated regulatory responses that, despite the
inﬂuence in the inﬂammatory process, were unable to induce tol-
erance and improve clinical signs, suggesting that the availability
of the antigen could be a crucial factor to determine regulatory
response.
The increase of IL-10 and TGF-b in the lymph nodes of the
300 lg MOG35–55 group on the 7th day suggests an immunosup-
pressive environment that probably could contribute to the devel-
opment of Tregs, which culminates in the delayed onset and
inﬂammation in the CNS and the lower demyelination on day 58
after immunization, when compared to the 100 lg MOG35–55
group.
A previous investigation reported on a similar mechanism
observed when the difference between susceptible and resistant
rat strains was studied [24]. After immunization of an Albino
Oxford resistant rat strain, a marked up-regulation of TGF-b
occurred in several hepatic structures. This developed an immuno-
suppressive environment in the liver, which contributed to the
lower susceptibility to the induction of EAE observed [24].
There is growing evidence that the generation of regulatory T
cells is necessary to maintain self-tolerance and prevent the onset
of autoimmune disease. It has been shown that such suppression
could act through the secretion of suppressor cytokines, such as
TGF-b or IL-10, and via a cell–cell contact mechanism [25–27].
Another study showed that the interplay between TGF-b and
dendritic cells is a key event in the control of EAE [28]. The lack
of TGF-b signaling in the innate system was sufﬁcient to induce
severe and spontaneous autoimmune encephalomyelitis, demon-
strated by early inﬁltration of T cells into CNS, activation of microg-
lia cells, inﬂammation in the CNS, locomotion dysfunction, and
premature death [28].
The present study observed an earlier increase of the inﬂamma-
tory inﬁltrate in the CNS in the 100 lg MOG35–55 group (7th day
after immunization). The results were consistent with previous
data that showed detectable number of leukocyte rolling and adhe-
sion in the cerebral microvasculature on days 7, 14 and 21 after
disease induction with 100 lg of MOG35–55 [29].
Fig. 3. Anti-inﬂammatory cytokine levels in the brain, spinal cord and lymph nodes. Cytokines levels of IL-10 and TGF-b in the brain (A and B), spinal cord (C and D) and
lymph nodes (E and F) of C57BL/6 mice non immunized and immunized with 100 or 300 lg of myelin oligodendrocyte (MOG35–55) peptide (n = 6 per group) were evaluated at
7, 10, 14, 21 and 58 days postimmunization. Brain, spinal cord and inguinal lymph nodes were removed and homogenized in extraction solution (100 mg of tissue per 1 ml).
Supernatants were collected to determine the concentration of IL-10 (A, C and E) and TGF-b (B, D and F), measured by ELISA. Each bar represents the arithmetic mean ± SEM.
⁄p < 0.05 versus non immunized group. p < 0.05 between the groups. Line, cytokine level of the non immunized group. Results are representative of three different
experiments.
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inﬂamed CNS had a time-based relationship with disease activity
and with the site of CNS lesions [18,30]. A time correlation
between chemokines release and cellular inﬁltration in the brain
was observed in the present study, when the production of CCL5
and CCL20 was evaluated for both groups. In addition, the peak
of chemokines overlaps the onset of clinical signs of the disease.
However, in the 300 lg MOG35–55 group, the lower cellular inﬁltra-
tion could be a consequence of the decrease in the chemokines
observed after the 10th day. The reduction of CCL5 and CCL20
has been suggested to be one of the factors responsible for the
improvement of clinical signs of EAE, when subjects are treatedwith an anthraquinone derivative [31]. A similar improvement,
due to reduced numbers of cells in CNS, was observed when
CCR5 T cells were depleted [32].
The migration of auto reactive T cells to the inﬂamed CNS is pro-
moted by the expression of the CCL20 receptor, while the CC-che-
mokine receptor 6 (CCR6) and the adhesion of leucocytes are
mediated by the production of CCL5 [29,31,33]. Additionally, an
amelioration of clinical signs, with reduction of adhered leucocytes
in the microcirculation of the CNS, was observed when CCL5 antag-
onists were used to treatment of EAE [34,35]. Furthermore, CCR6-
deﬁcient mice developed a normal Th17 response in peripheral
lymphoid organs, but failed to develop EAE [36].
Fig. 4. Chemokine levels in the brain. Chemokines levels in the brain of C57BL/6 in mice non immunized and immunized with 100 lg (A and B) or 300 lg (C and D) of myelin
oligodendrocyte (MOG35–55) peptide (n = 6 per group) were evaluated at 7, 10, 14, 21 and 58 days postimmunization. Brains were removed and homogenized in extraction
solution (100 mg of tissue per 1 ml). Supernatants were collected to determine the concentration of CCL5 (A and C) and CCL20 (B and D) and measured by ELISA. Each bar
represents the arithmetic mean ± SEM. ⁄p < 0.05 versus non immunized group. Results are representative of three different experiments.
Fig. 5. Intracellular expression of IL-17 and IFN-c. Expression of intracellular IL-17 (A) and IFN-c (B) in brain of C57BL/6 mice non immunized and immunized with 100 or
300 lg of myelin oligodendrocyte (MOG35–55) peptide were determined by ﬂow cytometry (n = 8 mice per group) at 7 and 10 days postimmunization. Cells were stained with
ﬂuorescence-conjugated antibodies to IL-17A (Alexa Fluor 488), CD4 (PerCP), IFN-c (PE-Cy7) and CD3 (PerCP). Bars represent mean ± SEM. ⁄p < 0.05 versus non immunized
group. p < 0.05 between the groups. Results are representative of three different experiments.
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of IFN-c and IL-17 on day 7 for the 100 lg MOG35–55 group and on
day 10 for the 300 lg MOG35–55 group was observed in the CNS.
The severity of EAE is related to the increased release of IFN-c
[4,37,38]. IL-17 has an important role as inﬂammatory mediator
in the development of EAE. As shown in previous studies, the use
of IL-17 blockers, or mice deﬁcient in IL-17, resulted in improve-
ment of the clinical signs of EAE [39,40]. Moreover, the transfer
of cells secreting IL-17 can induce EAE, but not the transfer of T
cells that secrete IFN-c [41].
The release of IL-6 and TGF-b could act through activation of
microglia, astrocytes, and antigen presentation in the CNS, or bypromoting the differentiation and expansion of Th17 cells, as
downstream inﬂammatory mediators of Th17 cells [42–45].
An inﬂammatory process determines the damage to myelin and
destruction of oligodendrocytes, and the injury and loss of axons.
Accumulating axonal and neuronal damage due to chronic neuro-
inﬂammation and neurodegeneration leads to increasing and per-
manent neurological dysfunction [46,47]. The earlier and more
intense inﬂammatory inﬁltrate observed in the CNS of the 100 lg
MOG35–55 group could be responsible for the more severe demye-
lination observed on day 58 after immunization.
The T cells producing IL-17, but not the T cells producing IFN-c,
are implicated in the initiation of inﬂammatory inﬁltrates in the
A.T. Dias et al. / Cellular Immunology 293 (2015) 87–94 93brain, and IFN-c has been shown to be more strongly associated
with the onset and the peak of disease [48–50]. In the present
study, the percentage of CD4+ T cells secreting IL-17 was more pro-
nounced on the 7th day after immunization, mainly in the 100 lg
MOG35–55 group. On the other hand, the expression of IFN-c was
higher on day 10, which was closest to the onset of disease in both
groups.
In conclusion, modiﬁcations only in the concentration of MOG
were able to change the time a regulatory response was triggered;
however, these changes were unable to modify the intensity of the
response, which explains the chronic progression of the disease in
both groups of mice.
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